These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 26856527)

  • 1. Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study.
    Herweijer E; Sundström K; Ploner A; Uhnoo I; Sparén P; Arnheim-Dahlström L
    Int J Cancer; 2016 Jun; 138(12):2867-74. PubMed ID: 26856527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
    Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
    Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of varying number of doses and timing between doses of quadrivalent HPV vaccine against severe cervical lesions.
    Dehlendorff C; Sparén P; Baldur-Felskov B; Herweijer E; Arnheim-Dahlström L; Ploner A; Uhnoo I; Kjaer SK
    Vaccine; 2018 Oct; 36(43):6373-6378. PubMed ID: 30249423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-related Effectiveness of Quadrivalent Human Papillomavirus Vaccine Against Cervical Intraepithelial Neoplasia: A Danish Nationwide Cohort Study.
    Verdoodt F; Dehlendorff C; Kjaer SK
    Clin Infect Dis; 2020 Feb; 70(4):608-614. PubMed ID: 30892587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study.
    Silverberg MJ; Leyden WA; Lam JO; Gregorich SE; Huchko MJ; Kulasingam S; Kuppermann M; Smith-McCune KK; Sawaya GF
    Lancet Child Adolesc Health; 2018 Oct; 2(10):707-714. PubMed ID: 30236379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries.
    Kjaer SK; Nygård M; Dillner J; Brooke Marshall J; Radley D; Li M; Munk C; Hansen BT; Sigurdardottir LG; Hortlund M; Tryggvadottir L; Joshi A; Das R; Saah AJ
    Clin Infect Dis; 2018 Jan; 66(3):339-345. PubMed ID: 29029053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial.
    Shing JZ; Hu S; Herrero R; Hildesheim A; Porras C; Sampson JN; Schussler J; Schiller JT; Lowy DR; Sierra MS; Carvajal L; Kreimer AR;
    Lancet Oncol; 2022 Jul; 23(7):940-949. PubMed ID: 35709811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
    Herweijer E; Leval A; Ploner A; Eloranta S; Simard JF; Dillner J; Netterlid E; Sparén P; Arnheim-Dahlström L
    JAMA; 2014 Feb; 311(6):597-603. PubMed ID: 24519299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
    Huh WK; Joura EA; Giuliano AR; Iversen OE; de Andrade RP; Ault KA; Bartholomew D; Cestero RM; Fedrizzi EN; Hirschberg AL; Mayrand MH; Ruiz-Sternberg AM; Stapleton JT; Wiley DJ; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Cuzick J; Garland SM; Kjaer SK; Bautista OM; Haupt R; Moeller E; Ritter M; Roberts CC; Shields C; Luxembourg A
    Lancet; 2017 Nov; 390(10108):2143-2159. PubMed ID: 28886907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human Papillomavirus Vaccination and Cervical Cytology Outcomes Among Urban Low-Income Minority Females.
    Hofstetter AM; Ompad DC; Stockwell MS; Rosenthal SL; Soren K
    JAMA Pediatr; 2016 May; 170(5):445-52. PubMed ID: 26974250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness of HPV vaccination against cervical neoplasia among birth cohorts ineligible for routine vaccination.
    Dong L; Nygård M; Støer NC; Klungsøyr O; Hansen BT
    Int J Cancer; 2023 Jul; 153(2):399-406. PubMed ID: 36866965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status.
    Sand FL; Kjaer SK; Frederiksen K; Dehlendorff C
    Int J Cancer; 2020 Aug; 147(3):641-647. PubMed ID: 31648368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study.
    Lamb F; Herweijer E; Ploner A; Uhnoo I; Sundström K; Sparén P; Arnheim-Dahlström L
    BMJ Open; 2017 Jun; 7(6):e015021. PubMed ID: 28600369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of prophylactic HPV vaccines against cervical abnormalities and HPV infection in Japan: The J-HERS 2021 multicenter study.
    Saeki Y; Saito M; Irie T; Itoh F; Enatsu A; Komura H; Fujii M; Fujii R; Hidaka N; Maehama T; Shirasu N; Waseda T; Shibata T; Takada E; Mibe K; Sakamoto J; Yamada S; Takakura M; Sasagawa T
    J Med Virol; 2024 Feb; 96(2):e29413. PubMed ID: 38314927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
    Apter D; Wheeler CM; Paavonen J; Castellsagué X; Garland SM; Skinner SR; Naud P; Salmerón J; Chow SN; Kitchener HC; Teixeira JC; Jaisamrarn U; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Mindel A; de Sutter P; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
    Clin Vaccine Immunol; 2015 Apr; 22(4):361-73. PubMed ID: 25651922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of HPV vaccination in Belize.
    Walwyn L; Janusz CB; Clark AD; Prieto E; Waight E; Largaespada N
    Vaccine; 2015 May; 33 Suppl 1():A174-81. PubMed ID: 25919158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness on high-grade cervical abnormalities and long-term safety of the quadrivalent human papillomavirus vaccine in Japanese women.
    Sakamoto M; Miyagi E; Sumi Y; Aisaka K; Kuno N; Nagano H; Asahara S; Han SR; Wakana A; Murata S; Sawata M; Tanaka Y
    J Infect Chemother; 2019 Jul; 25(7):520-525. PubMed ID: 30879979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of HPV vaccination against the development of high-grade cervical lesions in young Japanese women.
    Shiko Y; Konno R; Konishi H; Sauvaget C; Ohashi Y; Kakizoe T
    BMC Infect Dis; 2020 Nov; 20(1):808. PubMed ID: 33153446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.
    Dasbach EJ; Insinga RP; Yang YC; Pwu RF; Lac C; Elbasha EH
    Asian Pac J Cancer Prev; 2008; 9(3):459-66. PubMed ID: 18990021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.